XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
September 25 2007 - 11:12AM
PR Newswire (US)
VALLEY COTTAGE, New York, September 25 /PRNewswire-FirstCall/ --
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL)
announces today that its Annual General Meeting ("AGM") and
Extraordinary General Meeting ("EGM") was postponed for one week in
accordance with its articles of association due to the absence of a
quorum. The postponed AGM and EGM will take place at the Company,
Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100 at
4:00 pm and 4:30pm, respectively on October 2, 2007. Any proxy
votes received at any time up to 48 hours prior to the postponed
AGM and EGM will be included in the total votes counted for the AGM
and EGM. Those shareholders who have a valid "proof of ownership"
in Israel or a letter of representation from Computershare, the
Company's registrars, and attend the meeting in person will also be
permitted to vote. As a result of postponing the EGM, the Company
anticipates that the time and date for the cancellation of the
listing of its Ordinary Shares from the Official List of the United
Kingdom Listing Authority, being not less than 20 business days
from the date of the EGM as required by the United Kingdom Listing
Rules, is now 8:00 am (London Time) on October 31, 2007. About XTL
Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd. ("XTL") is
engaged in the development of therapeutics for the treatment of
neuropathic pain and hepatitis C. XTL is developing Bicifadine, a
serotonin and norepinephrine reuptake inhibitor, for the treatment
of diabetic neuropathic pain. XTL is also developing several novel
pre-clinical hepatitis C small molecule inhibitors. XTL also has an
active in-licensing and acquisition program designed to identify
and acquire additional drug candidates. XTL is publicly traded on
the NASDAQ, London, and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). Contact: Ron Bentsur Chief
Executive Officer Tel: +1-845-267-0707, ext. 225 DATASOURCE: XTL
Biopharmaceuticals Ltd CONTACT: Contact: Ron Bentsur, Chief
Executive Officer, Tel: +1-845-267-0707, ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024